Inhaled formoterol during one year in asthma: a comparison with salbutamol

Eighteen patients, who had previously taken part in a 2 wk cross-over comparison between formoterol and salbutamol, now took part in a one year double-blind study comparing salbutamol 200 micrograms b.i.d. with formoterol 12 micrograms b.i.d. Additional doses were taken when needed and were recorded. Ten patients were started on formoterol and eight on salbutamol. After one month, the patients were allowed to shift to the alternative drug. Two patients withdrew from the study. At the end of the study, 13 of 16 patients were on formoterol, thus showing a long-lasting preference for this drug. Forced expiratory volume in one second (FEV1) dose-response curves for inhaled salbutamol were repeatedly recorded during the study, and no tachyphylaxis was found. One patient stopped taking inhaled steroids but continued taking formoterol and theophylline. He deteriorated with a decreased response to salbutamol. After re-introduction of inhaled steroids his condition improved. This case indicates that effective bronchodilator therapy may mask the deterioration of asthma.

This article has been cited by other articles:

				R. Beasley, F. D. Martinez, A. Hackshaw, K. F. Rabe, P. J. Sterk, and R. Djukanovic Safety of long-acting {beta}-agonists: urgent need to clear the air remains Eur. Respir. J., January 1, 2009; 33(1): 3 - 5. [Full Text] [PDF]

				P.W. Ind, C. Villasante, R.J. Shiner, A. Pietinalho, N.G. Boszormenyi, S. Soliman, and O. Selroos Safety of formoterol by Turbuhaler(R) as reliever medication compared with terbutaline in moderate asthma Eur. Respir. J., October 1, 2002; 20(4): 859 - 866. [Abstract] [Full Text] [PDF]

				C.P. van Schayck, I.D. Bijl-Hofland, S.G.M. Cloosterman, H.T.M. Folgering, F.J.J. van der Elshout, and C. Van Weel Potential masking effect on dyspnoea perception by short- and long-acting {beta}2-agonists in asthma Eur. Respir. J., February 1, 2002; 19(2): 240 - 245. [Abstract] [Full Text] [PDF]

				J. Malolepszy, G. Boszormenyi Nagy, O. Selroos, P. Larsson, and R. Brander Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction Eur. Respir. J., December 1, 2001; 18(6): 928 - 934. [Abstract] [Full Text] [PDF]

				S. G. M. Cloosterman, I. D. Bijl-Hofland, C. L. A. van Herwaarden, R. P. Akkermans, F. J. J. van den Elshout, H. T. M. Folgering, and C. P. van Schayck A Placebo-Controlled Clinical Trial of Regular Monotherapy With Short-Acting and Long-Acting {beta}2-Agonists in Allergic Asthmatic Patients Chest, May 1, 2001; 119(5): 1306 - 1315. [Abstract] [Full Text] [PDF]

				J. BOUSQUET, P. K. JEFFERY, W. W. BUSSE, M. JOHNSON, and A. M. VIGNOLA Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1720 - 1745. [Full Text]

				B. J. Lipworth and I. Aziz Bronchodilator Response to Albuterol After Regular Formoterol and Effects of Acute Corticosteroid Administration* Chest, January 1, 2000; 117(1): 156 - 162. [Abstract] [Full Text] [PDF]

				A. E. TATTERSFIELD, D. S. POSTMA, P. J. BARNES, K. SVENSSON, C.-A. BAUER, P. M. O'BYRNE, C.-G. LÖFDAHL, R. A. PAUWELS, and A. ULLMAN Exacerbations of Asthma . A Descriptive Study of 425 Severe Exacerbations Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 594 - 599. [Abstract] [Full Text]

				A. Tuncer Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial Arch. Dis. Child., July 1, 1999; 81(1): 45 - 48. [Abstract] [Full Text]

				R. ANDREW MCIVOR, E. PIZZICHINI, M. O. TURNER, P. HUSSACK, F. E. HARGREAVE, and M. R. SEARS Potential Masking Effects of Salmeterol on Airway Inflammation in Asthma Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 924 - 930. [Abstract] [Full Text] [PDF]